Richard Pestell

Dr. Richard Pestell

Investor

Dr.  Pestell founded ProstaGene to rapidly bring to cancer patients the benefits of the prostate cancer testing and metastasis technologies discovered under his leadership at the Sidney Kimmel Cancer Center.  He is the inventor of record in the ProstaGene patents.  He is leading ProstaGene as an active Board Chair, is directly engaged in the recruitment of a fulltime CEO and a Senior Licensing Executive, and will continue to provide Board Chair leadership in the future.

Read More

Karen J. LaRochelle

Consultant

Consultant

History

LaRochelle Advisors, LLC 2013-2014 

Collaboration and Business Development Consultant for biotechnology and pharmaceutical companies in the US, EU and China.

BRISTOL-MYERS SQUIBB, Princeton, NJ 1993-2013

Executive Director, Business Development, Head of China Business Development

Categories: Management Team People

Emily Winn-Deen

Emily Winn-Deen

Senior Executive Consultant

Dr. Winn-Deen received her B.S. in Chemistry from Lehigh University and her Ph.D. in Chemistry from Boston University, and has over 30 years of experience in diagnostics product development. Most recently she was vice president for diagnostics product development at Illumina. Most recently, she was president of Rx Dx Advisors, a diagnostics consulting company, and vice president for genetics and oncology R&D at Cepheid, a molecular diagnostics company focusing on rapid nucleic acid testing located in Sunnyvale, CA. Read More

Categories: Management Team People

Chris Blaxland

Image
Chris Blaxland

Interim CEO

 

Chris Blaxland has over 30 years of experience in small and large companies, in general management, product development, and marketing and aspects of the industry.  His 20 years at GlaxoSmithKline (SmithKline Beecham and SK&F) included worldwide responsibility as Vice President of Strategic Product Development.  Chris is a Principal of Hunter Partners, LLC, a consultancy that provides advice and interim management for early to mid-stage pharmaceutical, biotech and medical device companies.

 

Chief Executive Officer (Permanent Position to Replace Acting CEO) – Open Position                                ProstaGene is currently seeking a CEO to direct its strategic and tactical planning, to oversee and execute its subcontracted development programs and prostate testing technology, and to provide oversight with the Executive Chairman to its Senior Licensing Executive (see below).

Categories: Management Team People

Dan W. Matthias

Dan Matthias

Investor

Dan W. Matthias is a member of the Board of Trustees of the Wistar Institute and its Intellectual Property and Scientific Advisory Committees as well as a member of the Board of Trustees of Thomas Jefferson University and its Biotechnology Committee.  He is the retired Chairman, CEO, and Co-Founder of  Mothers Work, Inc., a $500 million public company that manufactures and sells maternity apparel through over a thousand stores in the U.S. and Canada.  (Since his retirement, the company’s name has been changed to Destination Maternity and it continues to be listed on NASDAQ, as DEST.)

Prior to Mothers Work, Mr. Matthias was involved in the computer and electronics industry.  He was the President and Founder of a division of Exxon Corporation which  designed and produced the first desk top word processor, and a Director of Zilog, an early micro-computer chip startup, for which he led initial funding.   He is a graduate of Georgia Institute of Technology  (BEE, MSEE) and Harvard Business School  (MBA).

Rebecca C. Matthias

Rebecca Matthias

Investor

Rebecca Matthias has advised and assisted Dr. Pestell with strategic business matters and with financial planning and control, accounting, and reporting, and will continue to do so at no cost to the company.  She and Mr. Matthias (see above) provided the initial financial investments needed for worldwide patent filings and patent prosecution to protect the company’s technologies.

Rebecca Matthias is the former President, Founder and Chief Creative Officer of Destination Maternity Corporation (Nasdaq: DEST), a $500 million public company that manufactures and sells maternity apparel at over 3000 locations in the U.S., Canada and other countries.   She is a graduate of M.I.T (ME, Civil), Columbia University (M Arch), and The University of Pennsylvania (BA).  She serves on the Board of CSS Industries, a New York Stock Exchange company, and chairs its Nominating and Governance Committee; and is a director of Penn Series Funds, a division of Penn Mutual Corp, its Lead Director and Chair of the Audit Committee.  Formerly, she sat on the Board of The Russell Corporation, a New York Stock Exchange company, (until its sale to Berkshire Hathaway, Inc. in 2006).  Other emeritus Board positions include:  Drexel University, and The University of Pennsylvania, School of Arts and Sciences.  Ms. Matthias is the author of the book ‘Mothers Work’ (Doubleday), about her experiences starting up a business.

Since retiring from Destination Maternity, Ms. Matthias has become involved with a number of entrepreneurial ventures.  She is a founding investor/consultant at ProstaGene.  She also sits on the board of Honey Grow, a rapidly expanding chain of farm-to-table casual restaurants; and Lacoda, a software servicing company for the nascent peer-to-peer lending and asset based lending industries.

Categories: Management Team People

David T. Bonk

David T Bonk

Senior Executive Consultant

David brings 30 years of experience in the biopharmaceutical industry, and has served as:

  • Chair of the PhRMA Law Section.
  • The global head lawyer at Bristol-Myers Squibb in three different practice areas: Regulatory Law, Transactions and Intellectual Property.
  • A member of the BMS Research & Development Executive Committee for over 10 years.
  • The leader of multifunctional teams that handled high profile projects in areas such as intellectual property strategy/exclusivity challenges, scientific integrity investigations, complex orphan drug and pediatric research matters, management of the fallout from negative drug safety findings and the reassessment of a major company’s approach to risk and control.

Categories: Management Team People